Ferring Gains Option to FKD’s Phase III Bladder Cancer Gene Therapy Candidate – Genetic Engineering & Biotechnology News
Business Wire (press release) |
Ferring Gains Option to FKD's Phase III Bladder Cancer Gene Therapy Candidate
Genetic Engineering & Biotechnology News Ferring Pharmaceuticals said today it has acquired the option to secure global commercialization rights to FKD Therapies' Phase III bladder cancer gene therapy candidate nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), through an agreement whose value was … Ferring Signs Global Agreement to Commercialise Novel Gene Therapy for Bladder Cancer Patients Ferring commits to US oncology and cutting-edge research |
